Orthostatic intolerance

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Retrieved on: 
Mardi, mars 26, 2024
Fibromyalgia, DSM-IV codes, Epstein–Barr virus, WIPO, COVID-19, Patient, Conditional sentence, Orthostatic intolerance, System, Celecoxib, Anxiety, Medical statistics, EBV, MD, Fatigue, Treatment, Therapy, Patent, Pain, Valaciclovir, FDA, Pharmaceutical industry

ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that the World Intellectual Property Organization (WIPO) has published Virios’ global patent application titled “Valacyclovir and Celecoxib for the Treatment of Alzheimer’s and COVID-19”, which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.

Key Points: 
  • This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
  • An open-label, exploratory LC study sponsored by Virios demonstrated that treatment with the combination of valacyclovir and celecoxib resulted in clinical and statistically significant reductions in LC associated fatigue, orthostatic intolerance, pain and anxiety.
  • Previous estimates suggest that up to 10 million children in the US have also experienced LC.
  • There are no treatments approved by the FDA to treat the symptoms associated with LC, further highlighting the need for new treatments.

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Jeudi, février 29, 2024
Fibromyalgia, Research, FDA, Food, Drug development, Conditional sentence, Long COVID, Communication, Therapy, Fatigue, Orthostatic intolerance, Plasma protein binding, Pharmaceutical industry

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • General and administrative expenses for the fourth quarter of 2023 remained level with the fourth quarter of 2022 at $0.8 million.
  • As of December 31, 2023, Virios Therapeutics’ cash totaled $3.3 million.
  • The Company believes it has sufficient resources to fund operations into the fourth quarter of 2024.

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Retrieved on: 
Lundi, janvier 22, 2024
Conditional sentence, Fibromyalgia, Patient, Therapy, Orthostatic intolerance, Partnership, Fatigue, Chronic fatigue syndrome, Celecoxib, Valaciclovir, FDA, Pharmaceutical industry

ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”). The Company is targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025.

Key Points: 
  • The Company is targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025.
  • “We believe the profound unmet medical need associated with LC symptoms provides a unique and timely opportunity for Virios to advance our combination therapy, IMC-2,” said Greg Duncan, Chairman and CEO of Virios Therapeutics.
  • “There are currently no FDA-approved LC treatments, thus IMC-2 has potential to be one of the first therapies for addressing LC symptoms.
  • In addition, we have received input from the FDA on development requirements and key endpoints associated with advancing IMC-2 into Phase 2 development as a treatment for LC symptoms.

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Retrieved on: 
Mardi, janvier 2, 2024
PASC, Orthostatic intolerance, Food, Medical statistics, FDA, Disease, Conditional sentence, Fatigue, Therapy, Fibromyalgia, Vaccine

The FDA agreed that for the planned Phase 2 proof-of-concept study, Virios can use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint to assess the effectiveness of IMC-2 in treating PASC.

Key Points: 
  • The FDA agreed that for the planned Phase 2 proof-of-concept study, Virios can use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint to assess the effectiveness of IMC-2 in treating PASC.
  • The FDA recommended assessment of a range of IMC-2 doses, including valacyclovir doses above presently approved dosage strengths, to ensure effective inhibition of reactivated herpesvirus.
  • Following the receipt of the FDA’s feedback, Virios is currently exploring options to advance the IMC-2 LC Phase 2 research program.
  • IMC-2 has the potential to be one of the first approved treatments specifically for LC.

Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients

Retrieved on: 
Mercredi, mai 25, 2022
Department, Severe acute respiratory syndrome coronavirus 2, CEO, Risk, Lists of diseases, Private Securities Litigation Reform Act, Observational study, Institute for Music and Neurologic Function, NIH Intramural Research Program, National Institute of Neurological Disorders and Stroke, Leadership, National Institute, Patient, BVA, COVID-19, Mortality, NIH, FDA, Blood volume, Critical care, U.S. Department of Defense Strategy for Operating in Cyberspace, NINDS, Forward-looking statement, Department of Defense Serum Repository, Heart failure, Orthostatic intolerance, National, Exercise intolerance, SEC, GLOBE, Hypertension, Pharmaceutical industry, Stroke

Daxors BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure.

Key Points: 
  • Daxors BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure.
  • Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.
  • We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.
  • Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis.

COVID-19 Vaccination Well-tolerated in Patients with Mast Cell Activation Syndrome

Retrieved on: 
Mardi, février 8, 2022
Pain, Nausea, Dysautonomia, Orthostatic intolerance, Anaphylaxis, Research, American Academy of Allergy, Asthma, and Immunology, Vaccination, Asthma, B cell, Headache, Patient, AAAAI, RNA transfection, Population, American Academy, The Journal of Allergy and Clinical Immunology, Allergist, Red, Myalgia, Journal, Fever, Diarrhea, Chills, Neuropathic pain, Flushing, Fatigue, MCAS, Swelling, Hives, COVID-19, Pharmaceutical industry, Dairy product, Allergy, Immunology

MILWAUKEE, Feb. 8, 2022 /PRNewswire-PRWeb/ --Patients with suspected or confirmed mast cell activation syndrome (MCAS) can tolerate COVID-19 vaccination, according to an abstract being presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points: 
  • MILWAUKEE, Feb. 8, 2022 /PRNewswire-PRWeb/ --Patients with suspected or confirmed mast cell activation syndrome (MCAS) can tolerate COVID-19 vaccination, according to an abstract being presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).
  • The retrospective study analyzed 300 patients from a single academic center who had confirmed or suspected MCAS between December 2020 and November 2021.
  • Researchers found that 105 of the 300 patients in the study received at least one COVID-19 vaccine dose.
  • Few patients included in the study reported the immediate onset of symptoms associated with mast cell mediator release including flushing, urticaria, diarrhea or anaphylaxis.